Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Clinical trial NCT03516279 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03516279
Sponsor: ECOG-ACRIN Cancer Research Group
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Minimal Residual Disease

Start date: 2019-06-26
Primary completion: 2028-08-31
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.